These proteins are implicated in neurological disorders characterized by loss of function—SYNGAP1, CTNNB1, PURA, and MECP2. Our study revealed a consistent 2-fold increase in both protein and RNA levels, a finding particularly relevant for therapeutic development. This evidence concerns the gene MECP2 and nervous system disorder.